CANF Key Statistics, Chart & Performance
The current stock price of CANF is 0.1715 USD. In the past month the price decreased by -51.11%. In the past year, price decreased by -90.52%.
CANF Latest News, Press Relases and Analysis
CANF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
10 Bareket Street, Kiryat Matalon, P.O. Box 7537
Petah Tikva 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can you provide the latest stock price for CAN FITE BIOPHARMA LTD-ADR?
The current stock price of CANF is 0.1715 USD. The price decreased by -19.82% in the last trading session.
What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?
CANF does not pay a dividend.
What is the ChartMill technical and fundamental rating of CANF stock?
CANF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of CAN FITE BIOPHARMA LTD-ADR (CANF) based on its PE ratio?
CAN FITE BIOPHARMA LTD-ADR (CANF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
Can you provide the number of employees for CAN FITE BIOPHARMA LTD-ADR?
CAN FITE BIOPHARMA LTD-ADR (CANF) currently has 5 employees.
What is CAN FITE BIOPHARMA LTD-ADR worth?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 2.93M USD. This makes CANF a Nano Cap stock.
CANF Technical Analysis
CANF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CANF. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CANF Financial Highlights
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| Debt/Equity | 0 |
CANF Forecast & Estimates
7 analysts have analysed CANF and the average price target is 3.46 USD. This implies a price increase of 1916.21% is expected in the next year compared to the current price of 0.1715.